Seres Therapeutics (NASDAQ:MCRB) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Seres Therapeutics (NASDAQ:MCRB) in a research report report published on Thursday,Benzinga reports. The brokerage currently has a $10.00 price target on the biotechnology company’s stock.

A number of other analysts also recently commented on the company. StockNews.com downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. cut Seres Therapeutics from a “neutral” rating to an “underweight” rating in a report on Thursday, October 24th. Finally, Chardan Capital reissued a “buy” rating and set a $1.25 target price on shares of Seres Therapeutics in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $5.08.

Seres Therapeutics Stock Down 6.9 %

Shares of MCRB stock traded down $0.04 during mid-day trading on Thursday, reaching $0.55. The stock had a trading volume of 3,065,115 shares, compared to its average volume of 4,324,283. The business’s fifty day moving average is $0.86 and its 200-day moving average is $0.92. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $2.05.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period last year, the business earned $0.36 earnings per share. Equities analysts expect that Seres Therapeutics will post -0.92 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of MCRB. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Seres Therapeutics during the 1st quarter worth about $39,000. Providence Wealth Advisors LLC boosted its stake in shares of Seres Therapeutics by 49.5% during the 2nd quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 25,250 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Seres Therapeutics during the 2nd quarter worth approximately $64,000. Virtu Financial LLC acquired a new position in Seres Therapeutics in the 1st quarter valued at $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Seres Therapeutics in the 2nd quarter valued at $92,000. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.